This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of the formula I



I

in which

Ar denotes phenyl, naphthyl, biphenyl or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1,

X denotes -O-, -S-, $-(CH_2)_n-$, -C(=O)-, -CH(OH)-, $-(CH_2)_nO-$, $-O(CH_2)_n-$, $-(CH_2)_nS-$, $-S(CH_2)_n-$, $-(CH_2)_nNH-$, $-NH(CH_2)_n-$, $-(CH_2)_nNA-$, $-NA(CH_2)_n-$, -CHHal- or $-C(Hal)_2-$,

Y denotes O, S, $CH-NO_2$, $C(CN)_2$ or $N-R^4$,

Z denotes -Ar, -Ar-X-Ar, $-CH_2-Ar$ or $-CH_2-Ar-X-Ar$,

Het denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms,

R^1 denotes A, Ar', OR^3, SR^3, OAr', SAr', $N(R^3)_2$, NHAr', Hal, NO_2, CN, $(CH_2)_mCOOR^3$, $(CH_2)_mCON(R^3)_2$, COR^3, $S(O)_mA$, $S(O)_mAr'$, NHCOA, NHCOAr', $NHSO_2A$, $NHSO_2Ar'$, $SO_2N(R^3)_2$, $-O-(CH_2)_p-NH_2$, $-O-(CH_2)_p-NHA$, $-O-(CH_2)_p-NA_2$, $-NH-(CH_2)_p-NH_2$, $-NH-(CH_2)_p-NHA$, $-NH-(CH_2)_p-NA_2$, $-NA-(CH_2)_p-NH_2$, $-NA-(CH_2)_p-NHA$, $-NA-(CH_2)_p-NA_2$, $-O-(CH_2)_n-Het^1$ or Het^1,

R^3 denotes H, A or $-(CH_2)_nAr'$,

R^4 denotes H, CN, OH, A, $(CH_2)_mAr'$, COR^3, COAr', $S(O)_mA$ or $S(O)_mAr'$,

Ar' denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or

pentasubstituted by A, Ph, OH, OA, SH, SA, OPh, SPh, NH_2, NHA, NA_2, NHPh, Hal, NO_2, CN, $(CH_2)_mCOOH$, $(CH_2)_mCOOA$, $(CH_2)_mCONH_2$, $(CH_2)_mCONHA$, CHO, COA, $S(O)_mA$, $S(O)_mPh$, NHCOA, NHCOPh, $NHSO_2A$, $NHSO_2Ph$ or SO_2NH_2,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, COOR, COOH, NH_2, NO_2, OH or OA,

Het^1 denotes a monocyclic saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, CN, $(CH_2)_nOH$, $(CH_2)_nHal$, NH_2, =NH, =N-OH, =N-OA and/or carbonyl oxygen (=O),

A denotes alkyl having 1 to 10 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2 or 3,

m denotes 0, 1 or 2,

p denotes 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Original) Compounds according to Claim 1, in which

X denotes O or $-(CH_2)_n-$,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently Amended) Compounds according to Claim 1 ~~or 2~~, in which

Ar denotes Het or phenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

4. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1–3~~, in which

R^1 denotes A, OH, OA, NH_2, NHA, NA_2, Hal, $(CH_2)_mCONH_2$, $(CH_2)_mCONHA$, $(CH_2)_mCONA_2$, $-O-(CH_2)_p-NH_2$, $-O-(CH_2)_p-NHA$, $-O-(CH_2)_p-NA_2$, $-NH-(CH_2)_p-NH_2$, $-NH-(CH_2)_p-NHA$, $-NH-(CH_2)_p-NA_2$, $-NA-(CH_2)_p-NH_2$, $-NA-(CH_2)_p-NHA$, $-NA-(CH_2)_p-NA_2$, $-O-(CH_2)_n-Het^1$ or Het^1,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

5. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1–4~~, in which

Het denotes a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

6. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1–5~~, in which

Y denotes O,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

7. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1–6~~, in which

Z denotes -Ar,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-7~~, in which

Z denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by A, OH, OA, NH_2, NHA, NA_2, $-O-(CH_2)_p-NH_2$, $-O-(CH_2)_p-NHA$, $-O-(CH_2)_p-NA_2$, $-NH-(CH_2)_p-NH_2$, $-NH-(CH_2)_p-NHA$, $-NH-(CH_2)_p-NA_2$, $-NA-(CH_2)_p-NH_2$, $-NA-(CH_2)_p-NHA$, $-NA-(CH_2)_p-NA_2$, $-O-(CH_2)_n-Het^1$ or Het^1 or Hal,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-8~~, in which

X denotes O,

Ar denotes Het or phenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1,

R^1 denotes A, OH, OA, NH_2, NHA, NA_2, Hal, $-O-(CH_2)_p-NH_2$, $-O-(CH_2)_p-NHA$, $-O-(CH_2)_p-NA_2$, $-NH-(CH_2)_p-NH_2$, $-NH-(CH_2)_p-NHA$, $-NH-(CH_2)_p-NA_2$, $-NA-(CH_2)_p-NH_2$, $-NA-(CH_2)_p-NHA$, $-NA-(CH_2)_p-NA_2$, $(CH_2)_mCONH_2$, $(CH_2)_mCONHA$, $(CH_2)_mCONA_2$, $-O-(CH_2)_n-Het^1$ or Het^1

Het denotes a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms,

Het^1 denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or monosubstituted by A or $(CH_2)_nOH$,

Y denotes O,

Z denotes -Ar,

A denotes alkyl having 1 to 10 C atoms, in which, in addition, 1-7 H

atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

m denotes 0, 1 or 2,

p denotes 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

10. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-9~~, in which

X denotes O,

Ar denotes Het which is unsubstituted or mono-, di- or trisubstituted by R^1,

R^1 denotes $(CH_2)_mCONH_2$, $(CH_2)_mCONHA$ or $(CH_2)_mCONA_2$,

Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl,

Het^1 denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or monosubstituted by A or $(CH_2)_nOH$,

Y denotes O,

Z denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by A, OH, OA, NH_2, NHA, NA_2, $-O-(CH_2)_p-NH_2$, $-O-(CH_2)_p-NHA$, $-O-(CH_2)_p-NA_2$, $-NH-(CH_2)_p-NH_2$, $-NH-(CH_2)_p-NHA$, $-NH-(CH_2)_p-NA_2$, $-NA-(CH_2)_p-NH_2$, $-NA-(CH_2)_p-NHA$, $-NA-(CH_2)_p-NA_2$, $-O-(CH_2)_n-Het^1$ or Het^1 or Hal,

A denotes alkyl having 1 to 10 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

m denotes 0, 1 or 2,

p denotes 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

11. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-10~~, in which

Ar denotes phenyl, naphthyl, biphenyl or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1,

X denotes -O- or $-(CH_2)_n-$,

Y denotes O,

Z denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1, -phenylene-X-Ar, $-CH_2$-Ar or $-CH_2$-phenylene-X-Ar,

Het denotes a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms,

Het^1 denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or monosubstituted by A or $(CH_2)_nOH$,

R^1 denotes A, OH, OA, NH_2, NHA, NA_2, Hal, $(CH_2)_mCONH_2$, $(CH_2)_mCONHA$, $(CH_2)_mCONA_2$, $S(O)_mA$, $-O-(CH_2)_p-NH_2$, $-O-(CH_2)_p-NHA$, $-O-(CH_2)_p-NA_2$, $-NH-(CH_2)_p-NH_2$, $-NH-(CH_2)_p-NHA$, $-NH-(CH_2)_p-NA_2$, $-NA-(CH_2)_p-NH_2$, $-NA-(CH_2)_p-NHA$, $-NA-(CH_2)_p-NA_2$, $-O-(CH_2)_n-Het^1$ or Het^1

A denotes alkyl having 1 to 10 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2 or 3,

m denotes 0, 1 or 2,

p denotes 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

12. (Original) Compounds according to Claim 1, selected from the group

N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(4-chloro-3-trifluoromethylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{4-[5-(3-chloro-4-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{4-[5-(2-methoxy-5-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(3-chloro-4-methylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{4-[5-(3-chloro-6-methoxymethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(3-chloro-6-methoxymethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-methoxy-5-trifluoromethylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2,5-dimethoxy-4-chlorophenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(4-bromo-3-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(3-trifluoromethoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(4-tert-butylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(3,4-dichlorophenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(4-chloro-3-methyl-6-methoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2,4-dimethoxy-5-trifluoromethoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-dimethylamino-5-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-(2-methylaminoethoxy)-5-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-(2-dimethylaminoethoxy)-5-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-[(2-dimethylaminoethyl)methylamino]-5-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

13. (Currently Amended) Process for the preparation of compounds of the formula I according to claim 1 ~~Claims 1-10~~ and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, characterised in that

a) for the preparation of compounds of the formula I in which Y denotes O,

a compound of the formula II



II

,

in which X and Ar have the meanings indicated in Claim 1,

and L denotes Cl, Br, I or a free or reactively functionally modified OH group,

is reacted with a compound of the formula III

$Z\text{-}NH_2$ III ,

in which Z has the meaning indicated in Claim 1,

and/or

a base or acid of the formula I is converted into one of its salts.

14. (Original) Medicaments comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

15. (Original) Use of compounds according to Claim 1 and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios,

for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role.

16. (Original) Use according to Claim 15, which involves Raf kinase.

17. (Currently Amended) Use according to Claim 15 ~~or 16~~ of compounds of the formula I for the preparation of a medicament for the treatment of diseases caused, mediated and/or propagated by Raf kinases.

18. (Original) Use according to Claim 17, where the Raf kinase is selected from the group consisting of A-Raf, B-Raf and Raf-1.

19. (Original) Use according to Claim 18, where the diseases are selected from the group of hyperproliferative and non-hyperproliferative diseases.

20. (Currently Amended) Use according to Claim 17 ~~or 19~~, where the disease is cancer.

21. (Currently Amended) Use according to Claim 17 ~~or 19~~, where the disease is non-cancerous.

22. (Currently Amended) Use according to Claim 17~~, 19 or 21~~, where the non-cancerous diseases are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, Heliobacter pylori infection, influenza A, benign prostate hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.

23. (Currently Amended) Use according to claim 17 ~~one of Claims 17, 19 or 20~~, where the diseases are selected from the group consisting of melanoma, brain cancer, lung cancer, squamous epithelium cancer, bladder cancer, stomach can-

cer, pancreatic cancer, liver cancer, kidney cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, ovarian cancer, cervical cancer, prostate cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.

24. (Currently Amended) Use according to claim 15 ~~one of Claims 15-18~~, where the diseases are selected from the group arthritis, restenosis; fibrotic disorders; disorders mesangial cell proliferation, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation, solid tumours, rheumatic arthritis, diabetic neuropathy and neurodegenerative diseases.

25. (Currently Amended) Use according to claim 15 ~~one of Claims 15-18~~, where the diseases are selected from the group
rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, irritable bowel, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, kidney disease and angiogenesis disorders.

26. (Original) Intermediate compounds of the formula I-1



I-1

in which

Ar denotes phenyl, naphthyl, biphenyl or Het, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R^1,

X denotes -O-, -S-, $-(CH_2)_n-$, -C(=O)-, -CH(OH)-, $-(CH_2)_nO-$, $-O(CH_2)_n-$, $-(CH_2)_nS-$, $-S(CH_2)_n-$, $-(CH_2)_nNH-$, $-NH(CH_2)_n-$, $-(CH_2)_nNA-$,

$-NA(CH_2)_n-$, $-CHHal-$ or $-C(Hal)_2-$,

R denotes H or A,

Het denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms,

R^1 denotes A, Ar', OR^3, SR^3, OAr', SAr', $N(R^3)_2$, NHAr', Hal, NO_2, CN, $(CH_2)_mCOOR^3$, $(CH_2)_mCON(R^3)_2$, COR^3, $S(O)_mA$, $S(O)_mAr'$, NHCOA, NHCOAr', $NHSO_2A$, $NHSO_2Ar'$ or $SO_2N(R^3)_2$,

R^3 denotes H, A or $-(CH_2)_nAr'-$,

Ar' denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by A, Ph, OH, OA, SH, SA, OPh, SPh, NH_2, NHA, NA_2, NHPh, Hal, NO_2, CN, $(CH_2)_mCOOH$, $(CH_2)_mCOOA$, $(CH_2)_mCONH_2$, $(CH_2)_mCONHA$, CHO, COA, $S(O)_mA$, $S(O)_mPh$, NHCOA, NHCOPh, $NHSO_2A$, $NHSO_2Ph$ or SO_2NH_2,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, COOR, COOH, NH_2, NO_2, OH or OA,

A denotes alkyl having 1 to 10 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2 or 3,

m denotes 0, 1 or 2,

and solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

27. (Original) Intermediate compounds according to Claim 26

in which

X denotes O,

Ar denotes Het which is unsubstituted or mono-, di- or trisubstituted by R^1,

R denotes H or A,

R^1 denotes $(CH_2)_mCONH_2$, $(CH_2)_mCONHA$ or $(CH_2)_mCONA_2$,

Het denotes a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms,

and solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.